DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.

食物过敏是一个新出现的健康问题，发病率和严重性都在增加，特别是在儿童中，并持续到成年。自1990年以来，自我报告的花生过敏发病率显著上升，给医疗保健系统带来了越来越大的经济负担。由于没有获得批准的治疗方法，各种形式的免疫疗法已被评估，但通常不利于长期保护，并可能产生不良副作用。BlueWillow将应用其水包油纳米Vax纳米乳液粘膜佐剂(NE01)来研制抗花生过敏的疫苗。在这个SBIR项目中，第一阶段将包括配方活动和花生过敏小鼠模型的疗效评估。在第二阶段，该项目将评估临床前动物模型的长期保护，并参与支持IND的活动。

Food allergy is an emerging health problem with increasing incidence and severity, particularly in children, and continuing throughout adulthood. Since 1990, the incidence of self-reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare system. With no approved therapeutics available, various forms of immunotherapy have been evaluated but generally do not facilitate long-term protection and can have adverse side effects. BlueWillow will apply its oil-in-water NanoVax nanoemulsion mucosal adjuvant (NE01) to formulate a vaccine against peanut allergy. In this SBIR project, Phase I will consist of formulation activities and the evaluation of efficacy in a mouse model of peanut allergy. In phase II, the project will assess the long-term protection in preclinical animal models and engage in IND-enabling activities.